Ratings Medical Facilities Corporation

Equities

DR

CA58457V5036

Market Closed - Toronto S.E. Other stock markets 03:59:54 2024-05-06 pm EDT			5-day change	1st Jan Change
11.2 ^CAD	-0.44%		+0.18%	+24.72%

Apr. 18	Russia accuses Ukraine of shelling medical facilities and of killing medical staff	RE
Apr. 09	Israel purchases 40,000 tents for Rafah evacuation, Israeli media says	RE

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

The company's attractive earnings multiples are brought to light by a P/E ratio at 11.43 for the current year.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company does not generate enough profits, which is an alarming weak point.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	ESG Refinitiv
MEDICAL FACILITIES CORPORATION	+24.72%	201M	-
AIER EYE HOSPITAL GROUP CO., LTD.	-15.68%	17.21B	B+
BANGKOK DUSIT MEDICAL SERVICES	+4.50%	12.54B	B
IHH HEALTHCARE	+4.48%	11.71B	B+
APOLLO HOSPITALS ENTERPRISE LIMITED	+2.88%	10.43B	B+
ENCOMPASS HEALTH CORPORATION	+26.66%	8.51B	B
RAMSAY HEALTH CARE LIMITED	-1.92%	7.74B	A-
MOUWASAT MEDICAL SERVICES COMPANY	+20.39%	7.18B	D
THE ENSIGN GROUP, INC.	+3.42%	6.55B	B-
GLOBAL HEALTH LIMITED	+46.01%	4.5B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes